首页|揿针疗法联合参麦注射液提高晚期子宫颈癌化疗患者免疫功能的临床研究

揿针疗法联合参麦注射液提高晚期子宫颈癌化疗患者免疫功能的临床研究

扫码查看
目的:研究揿针疗法联合参麦注射液提高晚期子宫颈癌化疗患者免疫功能的效果.方法:临床研究对象选择 2018 年 8 月—2022 年 1 月在九江市第一人民医院接受治疗的晚期子宫颈癌患者 60 例,按照随机数字表法将其分为对照组和试验组,每组 30 例.对照组患者采用参麦注射液进行治疗,试验组在对照组基础上联合使用揿针疗法.观察两组T淋巴细胞亚群情况、卡氏(KPS)评分、肿瘤标志物指标、不良反应及治疗效果.结果:试验组治疗后CD4+和CD4+/CD8+均高于对照组,CD8+低于对照组,差异均有统计学意义(P<0.05).治疗前试验组KPS评分比较,差异无统计学意义(P>0.05);治疗后试验组的KPS评分显著高于对照组,差异有统计学意义(P<0.05).治疗前两组糖类抗原 125(CA125)、癌胚抗原(CEA)、糖类抗原 19-9(CA19-9),差异均无统计学意义(P>0.05);治疗后试验组各项肿瘤标志物指标均较对照组更低,差异均有统计学意义(P<0.05).试验组不良反应总发生率(10.00%)较对照组(33.33%)更低,差异有统计学意义(P<0.05).试验组患者总有效率(96.67%)较对照组(76.67%)更高,差异有统计学意义(P<0.05).结论:采取揿针疗法联合参麦注射液对晚期子宫颈癌化疗患者进行治疗,有利于降低不良反应发生率,提高治疗效果,加强患者免疫功能,改善肿瘤标志物指标水平.
Clinical Study on the Improvement of Immune Function in Patients with Advanced Cervical Cancer Undergoing Chemotherapy by Press Needle Therapy Combined with Shenmai Injection
Objective:To study the effect of press needle therapy combined with Shenmai Injection on improving immune function in patients with advanced cervical cancer undergoing chemotherapy.Method:A total of 60 patients with advanced cervical cancer who received treatment in Jiujiang NO.1 People's Hospital from August 2018 to January 2022 were selected as clinical research objects,and they were divided into control group and experimental group,with 30 cases in each group.The control group was treated with Shenmai Injection,and the experimental group was treated with press needle therapy on the basis of the control group.T lymphocyte subpopulation situation,Karnofsky(KPS)score,tumor markers,adverse reactions and therapeutic effect were observed in the two groups.Result:After treatment,CD4+ and CD4+/CD8+ in the experimental group were higher than those in the control group,while CD8+ was lower than that in the control group,the differences were statistically significant(P<0.05).There was no significant difference in KPS score before treatment(P>0.05).After treatment,the KPS score of experimental group was significantly higher than that of control group,the difference was statistically significant(P<0.05).There were no significant differences in carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)between two groups before treatment(P>0.05).After treatment,the tumor markers of the experimental group were lower than those of the control group,the differences were statistically significant(P<0.05).The total incidence of adverse reactions in experimental group(10.00%)was lower than that in control group(33.33%),the difference was statistically significant(P<0.05).The total effective rate of experimental group(96.67%)was higher than that of control group(76.67%),the difference was statistically significant(P<0.05).Conclusion:The combination of press needle therapy and Shenmai Injection in the treatment of patients with advanced cervical cancer undergoing chemotherapy is beneficial to reduce the incidence of adverse reactions,improve the therapeutic effect,strengthen the immune function of patients,and improve the levels of tumor markers.

Press needle therapyShenmai InjectionAdvanced cervical cancerImmune function

夏琴琴、石玲、梅耀国

展开 >

九江市第一人民医院门诊部 江西 九江 332000

九江市第一人民医院肿瘤三科 江西 九江 332000

九江市中医院中医肿瘤科 江西 九江 332000

揿针疗法 参麦注射液 晚期子宫颈癌 免疫功能

江西省中医药局科技项目

2022B169

2024

中国医学创新
中国保健协会

中国医学创新

影响因子:1.706
ISSN:1674-4985
年,卷(期):2024.21(9)
  • 20